Head and Neck Atopic Dermatitis: Therapeutic Response After Switching to Upadacitinib in Moderate-to-Severe Atopic Dermatitis Patients Who Had Inadequate Response to Dupilumab
SKIN The Journal of Cutaneous Medicine · 10.03.2026 · 10 (2) · s740
DOI: 10.25251/ztj3rn69 ↗Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.03.2026. Verfasst von Diego Ruiz Dasilva und 11 weiteren Autor:innen. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Head and neck (HN) atopic dermatitis (AD) imposes substantial burden on patients, given its visible nature and vulnerability to environmental triggers. Symptoms in these areas can cause psychosocial distress. While both upadacitinib (UPA) and dupilumab (DUPI) are established treatments for moderate-to-severe AD, persistent HN disease remains a therapeutic gap. This study evaluated the efficacy of switching to UPA in patients with moderate-to-severe AD who demonstrated inadequate HN response while receiving DUPI. This analysis evaluated data from patients with moderate-to-severe AD treated in two studies evaluating UPA vs DUPI: Heads Up (HU) and Level Up (LU). In HU, patients were randomized to DUPI 300mg or UPA 30mg (UPA30) before entering the open-label extension (OLE), which started at week 24. All patients, including those previously randomized to UPA and DUPI, received UPA30. In LU, patients were randomized to DUPI 300mg or UPA 15mg (UPA15) with dose escalation to UPA30 based on clinical response. The OLE began at week 16, at which point patients with inadequate disease response, as defined by an Eczema Area and Severity Index (EASI) score of
Zitieren
APA
Dasilva, D. R., Shahriari, M., Abe, M., Torres, T., Ribero, S., Yu, H., Miller, L., Altman, K., Lane, M., Moreira, A., Grada, A., & Bunick, C. (2026). Head and Neck Atopic Dermatitis: Therapeutic Response After Switching to Upadacitinib in Moderate-to-Severe Atopic Dermatitis Patients Who Had Inadequate Response to Dupilumab. SKIN The Journal of Cutaneous Medicine, 10(2), s740. https://doi.org/10.25251/ztj3rn69
Vancouver
Dasilva DR, Shahriari M, Abe M, Torres T, Ribero S, Yu H, et al. Head and Neck Atopic Dermatitis: Therapeutic Response After Switching to Upadacitinib in Moderate-to-Severe Atopic Dermatitis Patients Who Had Inadequate Response to Dupilumab. SKIN The Journal of Cutaneous Medicine. 2026;10(2):s740. doi:10.25251/ztj3rn69
BibTeX
@article{Dasilva2026,
author = {Dasilva, Diego Ruiz and Shahriari, Mona and Abe, Masatoshi and Torres, Tiago and Ribero, Simone and Yu, Henry and Miller, Lauren and Altman, Kathy and Lane, Michael and Moreira, Alvaro and Grada, Ayman and Bunick, Christopher},
title = {Head and Neck Atopic Dermatitis: Therapeutic Response After Switching to Upadacitinib in Moderate-to-Severe Atopic Dermatitis Patients Who Had Inadequate Response to Dupilumab},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2026},
volume = {10},
number = {2},
pages = {s740},
doi = {10.25251/ztj3rn69}
}
EUVIMED